Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics
ByJun Gong, MD,Edwin M. Posadas, MD,Neil Bhowmick, PhD,Hyung L. Kim, MD,Timothy J. Daskivich, MD,Amit Gupta, MD,Howard M. Sandler, MD,Mitchell Kamrava, MD,Zachary S. Zumsteg, MD,Stephen J. Freedland, MD,Robert A. Figlin, MD
Published: | Updated:
Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.
